Page 1

Mylan Inc (MYL)

Price: $22.98

Industry: Drugs Chaikin Power Gauge Report | Generated: Mon Mar 26 12:22 EDT 2012 Power Gauge Rating

MYL - Bullish TM

The Chaikin Power Gauge Rating for MYL is bullish due to very strong earnings performance and bullish price/volume activity. The rating also reflects negative expert opinions. MYL's earnings performance is very strong as a result of an upward trend in earnings this year and a relatively low projected P/E ratio.

News Sentiment Rating

Bullish MYL Mylan Inc

March 21, 2012

TM

Chaikin Sentiment Gauge for MYL is bullish. There is currently a significant positive sentiment within news stories concerning MYL.

News Sentiment :Positive

Power Trend - 5 Year Chart

The Power Gauge distills a 20 factor model into a concise picture of a stock's potential.

I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here

High Potential

Neutral

Low Potential

www.chaikinpowertools.com


Financials & Earnings

Financial Metrics Rating

Financial Metrics

Neutral

LT Debt/Equity Ratio

MYL's financial metrics are neutral. The company has high revenue per share and is carrying too much long term debt relative to its industry group.

Price to Book Value

The rank is based on a high long term debt to equity ratio relative to its industry group, high price to book value ratio, high return on equity, low price to sales ratio and relatively low cash flow.

Return on Equity

Price to Sales Ratio

Business Value

Assets and Liabilities

Valuation

Returns

Ratio

TTM

Ratio

TTM

Ratio

Current Ratio

1.39

Price/Book

2.80

Return on Invest

10.6%

LT Debt/Equity

1.38

Price/Sales

1.60

Return on Equity

24.2%

Earnings Performance

TTM

Earnings Performance Rating

Very Bullish

Earnings Growth

MYL's earnings performance has been very strong. The company experienced superior earnings growth in the past 12 months and is priced relatively low compared to next year's projected EPS.

Earnings Surprise

Earnings Trend

The rank is based on an upward trend in earnings this year, a relatively low projected P/E ratio and consistent earnings over the past 5 years.

Projected P/E Ratio

Earnings Consistency

5 Year Revenue and Earnings Growth

Revenue(M) Rev % Growth EPS EPS % Growth

EPS Estimates

12/07

12/08

12/09

12/10

12/11

2,666.02

5,137.58

5,092.78

5,450.52

6,129.82

65.40%

92.71%

-0.87%

7.02%

12.46%

$-4.91

$-1.05

$0.31

$0.69

$1.25

-586.14%

78.62%

129.52%

122.58%

81.16%

EPS Surprise

Factor

Actual EPS Prev

EST EPS Current

Change

$0.24

$0.52

+0.28

Quarterly EPS Yearly EPS Factor

$1.25

$2.44

+1.19

Actual EPS Growth

Est EPS Growth

Change

35.35%

9.51%

-25.84

3-5 year EPS

EPS Quarterly Results Estimate

Actual

Difference

% Difference

FY

Qtr 1

Qtr 2

Qtr 3

Qtr 4

Total

Latest Qtr

$0.50

$0.53

$0.03

1 Qtr Ago

$0.51

$0.55

$0.04

6.00

12/09

$0.23

$0.19

$-0.13

$0.01

$0.30

7.84

12/10

$0.20

$0.17

$0.35

$0.01

$0.73

2 Qtr Ago

$0.45

$0.52

3 Qtr Ago

$0.44

$0.44

$0.07

15.56

12/11

$0.24

$0.34

$0.37

$0.30

$1.25

$0.00

0.00

Fiscal Year End Month is December.

I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here

www.chaikinpowertools.com


Price Trend & Expert Opinions Price/Volume Activity

Price/Volume Activity Rating

Bullish

Relative Strength vs Market

Price and volume activity for MYL is bullish. MYL is experiencing sustained buying and has outperformed the S&P 500 over 26 weeks.

Chaikin Money Flow

Price Trend

The rank for MYL is based on positive Chaikin money flow.

Price Trend ROC

Volume Trend

Relative Strength vs S&P500 Index

Chaikin Money Flow

Chart shows whether MYL is performing better or worse than the market.

Chaikin Money Flow analyzes supply and demand for a company's stock.

Price Activity

Price Activity

Volume Activity

Factor

Value

Factor

52 Week High

25.23

% Change Price - 4 Weeks

-3.00%

Average Volume 20 Days

5,238,400

52 Week Low

16.16

% Change Price - 24 Weeks

31.01%

Average Volume 90 Days

5,543,251

% Change Price - 4 Wks Rel to S&P

-5.33%

Chaikin Money Flow Persistency

% Change Price - 24 Wks Rel to S&P

9.25%

% Change YTD Rel S&P 500

-4.47%

Expert Opinions

Value

Factor

Value

69%

Expert Opinions

Bearish

Earnings Estimate Revisions

Expert opinions about MYL are negative. Analysts's opinions on MYL have been more negative recently and short interest in MYL is high.

Short Interest

Insider Activity

The rank for MYL is based on analysts revising earnings estimates upward, a high short interest ratio, insiders purchasing stock, pessimistic analyst opinions and relative weakness of the stock versus the Drugs industry group.

Analyst Opinions

Relative Strength vs Industry

Earnings Estimate Revisions Current Current Qtr Next Qtr

0.52 0.58 Current

Current FY

2.44

Analyst Recommendations

7 Days Ago % Change 0.52 0.58

0.00% 0.00%

30 Days Ago % Change 2.43

0.01

Factor Mean this Week Mean Last Week

EPS Estimates Revision Summary Value

Buy 0.00

Mean 5 Weeks Ago

Buy

Last 4 Weeks

Down

Up

Down

Curr Qtr

0

1

0

3

Curr Yr

0

0

1

0

Next Qtr

1

0

1

2

Next Yr

0

0

2

0

Buy

Change

I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here

Last Week Up

www.chaikinpowertools.com


The Company & Its Competitors

News Headlines for MYL

MYL's Competitors in Drugs Company

Power Gauge

Historic EPS growth

Projected EPS growth

Profit Margin

PEG

PE

Revenue(M)

MYL

35.35%

9.51%

8.76%

0.99

11.26

6,130

IPXL

50.69%

15.61%

12.77%

0.86

24.09

513

WPI

18.82%

8.68%

5.69%

1.31

13.70

4,584

TEVA

16.94%

8.40%

15.07%

0.92

8.65

18,312

PRX

12.80%

7.76%

-2.82%

1.35

11.20

926

RDY

38.12%

25.00%

15.63%

0.70

19.28

1,677

SCR

14.96%

5.17%

8.74%

3.94

21.51

324

HITK

24.65%

-

22.59%

-

9.20

191

BRIEF: Mylan receives approval for generic Boniva - Mar 21, 2012 Mylan One of First to Launch Generic Version of Boniva® - Mar 20, 2012 Mylan Canada Receives Health Canada Approval for Generic Version of Crestor® - Mar 15, 2012 Mylan Launches First Equivalent Product to Lexapro® Tablets - Feb 29, 2012 Mylan Receives Tentative FDA Approval Through PEPFAR for Pediatric HIV/AIDS Therapy - Feb 23, 2012

Company Details

Company Profile

Mylan Inc 1500 CORPORATE DRIVE SUITE 400 CANONSBURG, PA 15317 USA Phone: 724-514-1800 Fax: 724-514-1870 Website: http://http://www.mylan.com Full Time Employees: 18,000 Sector: Medical

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.

Power Gauge Ratings are created using a relative ranking system that assigns a rank of 0 to 100 (100 being the highest) to each stock in the universe. Rank is calculated by evaluating each of the stocks factors and combining them into a single number using a weighting formula. A stock's rank ranges from 100-0, where 100 is the strongest, and a rank of 95 indicates the stock is better than 95% of the stocks in the universe. Chaikin Stock Research(CSR) is not registered as a securities broker dealer or investment advisor with either the U.S. Securities and Exchange Commission or with any state securities regulatory authority. CSR is not responsible for trades executed by users of this research report, our web site or mobile app based on the information included herein. The information presented in this report does not represent a recommendation to buy or sell stocks or any financial instrument nor is it intended as an endorsement of any security or investment. The information in this report is generic by nature and is not personalized to the specific financial situation of any individual. The user bears complete responsibility for their own investment research and should seek the advice of a qualified investment professional before making any investment decisions. Copyright (c) 1978-(Present) by ZACKS Investment Research, Inc ("ZACKS"). The information, data, analyses and opinions contained herein (1) includes the confidential and proprietary information of ZACKS, (2) may not be copied or redistributed, for any purpose, (3) does not constitute investment advice offered by ZACKS, (4) are provided solely for informational purposes, and (5) are not warranted or represented to be correct, complete, accurate or timely. ZACKS shall not be responsible for investment decisions, damages or other losses resulting from, or related to, use of this information, data, analyses or opinions. Past performance is no guarantee of future performance. ZACKS is not affiliated with Chaikin Power Tools. This report from Chaikin Power Tools is for informational purposes only and is not a recommendation to buy or sell securities.

LM 2.3 DS 3.0 LS 2.1

Data Provided by ZACKS Investment Research, Inc., www.zacks.com

Special offers to trade stocks from optionsXpress: www.chaikinpowertools.com

Stock Research Report for MYL as of 3/26/2012 - Chaikin Power Tools  

To order a free Chaikin Power Gauge stock research report for MYL go to http://www.chaikinpowertools.com/reports

Read more
Read more
Similar to
Popular now
Just for you